#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Interview with Reggie Bibbs on his life with neurofibromatosis
1-1	0-9	Interview	event[1]	new[1]	_	_
1-2	10-14	with	event[1]	new[1]	_	_
1-3	15-21	Reggie	event[1]|person[2]	new[1]|new[2]	ana	1-6[0_2]
1-4	22-27	Bibbs	event[1]|person[2]	new[1]|new[2]	_	_
1-5	28-30	on	event[1]	new[1]	_	_
1-6	31-34	his	event[1]|person|abstract[4]	new[1]|giv|new[4]	coref	17-1[100_0]
1-7	35-39	life	event[1]|abstract[4]	new[1]|new[4]	_	_
1-8	40-44	with	event[1]|abstract[4]	new[1]|new[4]	_	_
1-9	45-62	neurofibromatosis	event[1]|abstract[4]|abstract	new[1]|new[4]|new	coref	3-5

#Text=Friday , December 14 , 2007
2-1	63-69	Friday	time	new	appos	2-3[8_0]
2-2	70-71	,	_	_	_	_
2-3	72-80	December	time|time[8]	new|giv[8]	_	_
2-4	81-83	14	time[8]	giv[8]	_	_
2-5	84-85	,	time[8]	giv[8]	_	_
2-6	86-90	2007	time[8]|time	giv[8]|new	_	_

#Text=Infobox : What is neurofibromatosis ?
3-1	91-98	Infobox	abstract	new	coref	18-26[110_0]
3-2	99-100	:	_	_	_	_
3-3	101-105	What	_	_	_	_
3-4	106-108	is	_	_	_	_
3-5	109-126	neurofibromatosis	abstract	giv	coref	4-1
3-6	127-128	?	_	_	_	_

#Text=Neurofibromatosis ( NF ) is a genetic condition causing benign tumors ( neurofibromas ) to grow along certain types of nerves and , in addition , it can affect the development of bones or skin .
4-1	129-146	Neurofibromatosis	abstract	giv	appos	4-3
4-2	147-148	(	_	_	_	_
4-3	149-151	NF	abstract	giv	coref	4-6[14_0]
4-4	152-153	)	_	_	_	_
4-5	154-156	is	_	_	_	_
4-6	157-158	a	abstract[14]	giv[14]	ana	4-27[0_14]
4-7	159-166	genetic	abstract[14]	giv[14]	_	_
4-8	167-176	condition	abstract[14]	giv[14]	_	_
4-9	177-184	causing	abstract[14]	giv[14]	_	_
4-10	185-191	benign	abstract[14]|object[15]	giv[14]|new[15]	coref	7-22[39_15]
4-11	192-198	tumors	abstract[14]|object[15]	giv[14]|new[15]	_	_
4-12	199-200	(	abstract[14]	giv[14]	_	_
4-13	201-214	neurofibromas	abstract[14]|abstract	giv[14]|new	_	_
4-14	215-216	)	abstract[14]	giv[14]	_	_
4-15	217-219	to	abstract[14]	giv[14]	_	_
4-16	220-224	grow	abstract[14]	giv[14]	_	_
4-17	225-230	along	abstract[14]	giv[14]	_	_
4-18	231-238	certain	abstract[14]|place[17]	giv[14]|new[17]	_	_
4-19	239-244	types	abstract[14]|place[17]	giv[14]|new[17]	_	_
4-20	245-247	of	abstract[14]|place[17]	giv[14]|new[17]	_	_
4-21	248-254	nerves	abstract[14]|place[17]|abstract	giv[14]|new[17]|new	coref	15-17[91_0]
4-22	255-258	and	abstract[14]	giv[14]	_	_
4-23	259-260	,	abstract[14]	giv[14]	_	_
4-24	261-263	in	abstract[14]	giv[14]	_	_
4-25	264-272	addition	abstract[14]	giv[14]	_	_
4-26	273-274	,	abstract[14]	giv[14]	_	_
4-27	275-277	it	abstract[14]|abstract	giv[14]|giv	coref	5-6[24_0]
4-28	278-281	can	abstract[14]	giv[14]	_	_
4-29	282-288	affect	abstract[14]	giv[14]	_	_
4-30	289-292	the	abstract[14]|event[20]	giv[14]|new[20]	_	_
4-31	293-304	development	abstract[14]|event[20]	giv[14]|new[20]	_	_
4-32	305-307	of	abstract[14]|event[20]	giv[14]|new[20]	_	_
4-33	308-313	bones	abstract[14]|event[20]|object	giv[14]|new[20]|new	_	_
4-34	314-316	or	abstract[14]|event[20]	giv[14]|new[20]	_	_
4-35	317-321	skin	abstract[14]|event[20]|object	giv[14]|new[20]|new	coref	7-8[32_0]
4-36	322-323	.	_	_	_	_

#Text=There are several variants of the disease but type 1 and type 2 NF account for the vast majority of cases .
5-1	324-329	There	_	_	_	_
5-2	330-333	are	_	_	_	_
5-3	334-341	several	abstract[23]	new[23]	_	_
5-4	342-350	variants	abstract[23]	new[23]	_	_
5-5	351-353	of	abstract[23]	new[23]	_	_
5-6	354-357	the	abstract[23]|abstract[24]	new[23]|giv[24]	coref	5-14[0_24]
5-7	358-365	disease	abstract[23]|abstract[24]	new[23]|giv[24]	_	_
5-8	366-369	but	_	_	_	_
5-9	370-374	type	abstract[25]	new[25]	coref	7-19[37_25]
5-10	375-376	1	abstract[25]	new[25]	_	_
5-11	377-380	and	_	_	_	_
5-12	381-385	type	abstract[26]	new[26]	_	_
5-13	386-387	2	abstract[26]	new[26]	_	_
5-14	388-390	NF	abstract	giv	coref	6-2
5-15	391-398	account	_	_	_	_
5-16	399-402	for	_	_	_	_
5-17	403-406	the	_	_	_	_
5-18	407-411	vast	_	_	_	_
5-19	412-420	majority	_	_	_	_
5-20	421-423	of	_	_	_	_
5-21	424-429	cases	_	_	_	_
5-22	430-431	.	_	_	_	_

#Text=The disease manifestations can vary from very mild to severe .
6-1	432-435	The	event[29]	new[29]	_	_
6-2	436-443	disease	abstract|event[29]	giv|new[29]	coref	10-1
6-3	444-458	manifestations	event[29]	new[29]	_	_
6-4	459-462	can	_	_	_	_
6-5	463-467	vary	_	_	_	_
6-6	468-472	from	_	_	_	_
6-7	473-477	very	_	_	_	_
6-8	478-482	mild	_	_	_	_
6-9	483-485	to	_	_	_	_
6-10	486-492	severe	_	_	_	_
6-11	493-494	.	_	_	_	_

#Text=Major symptoms include growths on and under the skin ; skin pigmentations called café au lait spots in type 1 ; acoustic nerve tumors and consequent hearing loss in type 2 .
7-1	495-500	Major	abstract[30]	new[30]	_	_
7-2	501-509	symptoms	abstract[30]	new[30]	_	_
7-3	510-517	include	_	_	_	_
7-4	518-525	growths	abstract[31]	new[31]	coref	8-1[0_31]
7-5	526-528	on	abstract[31]	new[31]	_	_
7-6	529-532	and	abstract[31]	new[31]	_	_
7-7	533-538	under	abstract[31]	new[31]	_	_
7-8	539-542	the	abstract[31]|object[32]	new[31]|giv[32]	coref	7-11[0_32]
7-9	543-547	skin	abstract[31]|object[32]	new[31]|giv[32]	_	_
7-10	548-549	;	_	_	_	_
7-11	550-554	skin	object|abstract[34]	giv|new[34]	_	_
7-12	555-568	pigmentations	abstract[34]	new[34]	_	_
7-13	569-575	called	abstract[34]	new[34]	_	_
7-14	576-580	café	abstract[34]|place|place[36]	new[34]|new|new[36]	_	_
7-15	581-583	au	abstract[34]|place[36]	new[34]|new[36]	_	_
7-16	584-588	lait	abstract[34]|place[36]	new[34]|new[36]	_	_
7-17	589-594	spots	abstract[34]|place[36]	new[34]|new[36]	_	_
7-18	595-597	in	abstract[34]	new[34]	_	_
7-19	598-602	type	abstract[34]|abstract[37]	new[34]|giv[37]	coref	7-30[43_37]
7-20	603-604	1	abstract[34]|abstract[37]	new[34]|giv[37]	_	_
7-21	605-606	;	_	_	_	_
7-22	607-615	acoustic	object[39]|object[40]	giv[39]|giv[40]	coref|coref	7-22[40_39]|9-7[53_40]
7-23	616-621	nerve	object|object[39]|object[40]	new|giv[39]|giv[40]	_	_
7-24	622-628	tumors	object[39]|object[40]	giv[39]|giv[40]	_	_
7-25	629-632	and	object[40]	giv[40]	_	_
7-26	633-643	consequent	object[40]|event[42]	giv[40]|new[42]	_	_
7-27	644-651	hearing	object[40]|abstract|event[42]	giv[40]|new|new[42]	_	_
7-28	652-656	loss	object[40]|event[42]	giv[40]|new[42]	_	_
7-29	657-659	in	object[40]|event[42]	giv[40]|new[42]	_	_
7-30	660-664	type	object[40]|event[42]|abstract[43]	giv[40]|new[42]|giv[43]	coref	10-31[62_43]
7-31	665-666	2	object[40]|event[42]|abstract[43]|abstract	giv[40]|new[42]|giv[43]|giv	_	_
7-32	667-668	.	_	_	_	_

#Text=Growths can affect nearly all parts of the body , and pressure on nearby structures can cause a wide variety of complications .
8-1	669-676	Growths	abstract	giv	_	_
8-2	677-680	can	_	_	_	_
8-3	681-687	affect	_	_	_	_
8-4	688-694	nearly	abstract[46]	new[46]	_	_
8-5	695-698	all	abstract[46]	new[46]	_	_
8-6	699-704	parts	abstract[46]	new[46]	_	_
8-7	705-707	of	abstract[46]	new[46]	_	_
8-8	708-711	the	abstract[46]|object[47]	new[46]|new[47]	coref	18-22[109_47]
8-9	712-716	body	abstract[46]|object[47]	new[46]|new[47]	_	_
8-10	717-718	,	_	_	_	_
8-11	719-722	and	_	_	_	_
8-12	723-731	pressure	abstract[48]	new[48]	_	_
8-13	732-734	on	abstract[48]	new[48]	_	_
8-14	735-741	nearby	abstract[48]|object[49]	new[48]|new[49]	coref	15-11[90_49]
8-15	742-752	structures	abstract[48]|object[49]	new[48]|new[49]	_	_
8-16	753-756	can	_	_	_	_
8-17	757-762	cause	_	_	_	_
8-18	763-764	a	abstract[50]	new[50]	_	_
8-19	765-769	wide	abstract[50]	new[50]	_	_
8-20	770-777	variety	abstract[50]	new[50]	_	_
8-21	778-780	of	abstract[50]	new[50]	_	_
8-22	781-794	complications	abstract[50]|abstract	new[50]|new	_	_
8-23	795-796	.	_	_	_	_

#Text=There is a small risk that the tumors transform into malignant cancerous lesions .
9-1	797-802	There	_	_	_	_
9-2	803-805	is	_	_	_	_
9-3	806-807	a	abstract[52]	new[52]	_	_
9-4	808-813	small	abstract[52]	new[52]	_	_
9-5	814-818	risk	abstract[52]	new[52]	_	_
9-6	819-823	that	abstract[52]	new[52]	_	_
9-7	824-827	the	abstract[52]|object[53]	new[52]|giv[53]	coref	16-2[0_53]
9-8	828-834	tumors	abstract[52]|object[53]	new[52]|giv[53]	_	_
9-9	835-844	transform	abstract[52]	new[52]	_	_
9-10	845-849	into	abstract[52]	new[52]	_	_
9-11	850-859	malignant	abstract[52]|object[54]	new[52]|new[54]	_	_
9-12	860-869	cancerous	abstract[52]|object[54]	new[52]|new[54]	_	_
9-13	870-877	lesions	abstract[52]|object[54]	new[52]|new[54]	_	_
9-14	878-879	.	_	_	_	_

#Text=NF is one of the most common single-gene human diseases ; around 1 in 2,500-4,000 live births are affected by NF-1 , whereas NF-2 occurs in about 1 in 50,000-120,000. Both type 1 and 2 are autosomal dominant conditions , meaning that only one copy of the mutated gene need be inherited to pass the disorder .
10-1	880-882	NF	abstract	giv	coref	11-7
10-2	883-885	is	_	_	_	_
10-3	886-889	one	abstract[56]	new[56]	_	_
10-4	890-892	of	abstract[56]	new[56]	_	_
10-5	893-896	the	abstract[56]|abstract[57]	new[56]|new[57]	_	_
10-6	897-901	most	abstract[56]|abstract[57]	new[56]|new[57]	_	_
10-7	902-908	common	abstract[56]|abstract[57]	new[56]|new[57]	_	_
10-8	909-920	single-gene	abstract[56]|abstract[57]	new[56]|new[57]	_	_
10-9	921-926	human	abstract[56]|abstract[57]	new[56]|new[57]	_	_
10-10	927-935	diseases	abstract[56]|abstract[57]	new[56]|new[57]	_	_
10-11	936-937	;	_	_	_	_
10-12	938-944	around	event[58]	new[58]	_	_
10-13	945-946	1	event[58]	new[58]	_	_
10-14	947-949	in	event[58]	new[58]	_	_
10-15	950-961	2,500-4,000	event[58]	new[58]	_	_
10-16	962-966	live	event[58]	new[58]	_	_
10-17	967-973	births	event[58]	new[58]	_	_
10-18	974-977	are	_	_	_	_
10-19	978-986	affected	_	_	_	_
10-20	987-989	by	_	_	_	_
10-21	990-994	NF-1	abstract	new	coref	12-5
10-22	995-996	,	_	_	_	_
10-23	997-1004	whereas	_	_	_	_
10-24	1005-1009	NF-2	abstract|abstract[63]	new|giv[63]	coref|coref	10-24[63_62]|12-7[75_0]
10-25	1010-1016	occurs	abstract[63]	giv[63]	_	_
10-26	1017-1019	in	abstract[63]	giv[63]	_	_
10-27	1020-1025	about	time[61]|abstract[63]	giv[61]|giv[63]	_	_
10-28	1026-1027	1	time[61]|abstract[63]	giv[61]|giv[63]	_	_
10-29	1028-1030	in	time[61]|abstract[63]	giv[61]|giv[63]	_	_
10-30	1031-1046	50,000-120,000.	time[61]|abstract[63]	giv[61]|giv[63]	_	_
10-31	1047-1051	Both	abstract[62]|abstract[63]	giv[62]|giv[63]	_	_
10-32	1052-1056	type	abstract[62]|abstract[63]	giv[62]|giv[63]	_	_
10-33	1057-1058	1	abstract[62]|abstract[63]	giv[62]|giv[63]	_	_
10-34	1059-1062	and	abstract[62]|abstract[63]	giv[62]|giv[63]	_	_
10-35	1063-1064	2	abstract[62]|abstract[63]	giv[62]|giv[63]	_	_
10-36	1065-1068	are	abstract[63]	giv[63]	_	_
10-37	1069-1078	autosomal	abstract[63]	giv[63]	_	_
10-38	1079-1087	dominant	abstract[63]	giv[63]	_	_
10-39	1088-1098	conditions	abstract[63]	giv[63]	_	_
10-40	1099-1100	,	abstract[63]	giv[63]	_	_
10-41	1101-1108	meaning	abstract[63]	giv[63]	_	_
10-42	1109-1113	that	abstract[63]	giv[63]	_	_
10-43	1114-1118	only	abstract[63]|object[64]	giv[63]|new[64]	_	_
10-44	1119-1122	one	abstract[63]|object[64]	giv[63]|new[64]	_	_
10-45	1123-1127	copy	abstract[63]|object[64]	giv[63]|new[64]	_	_
10-46	1128-1130	of	abstract[63]|object[64]	giv[63]|new[64]	_	_
10-47	1131-1134	the	abstract[63]|object[64]|abstract[65]	giv[63]|new[64]|new[65]	coref	12-1[73_65]
10-48	1135-1142	mutated	abstract[63]|object[64]|abstract[65]	giv[63]|new[64]|new[65]	_	_
10-49	1143-1147	gene	abstract[63]|object[64]|abstract[65]	giv[63]|new[64]|new[65]	_	_
10-50	1148-1152	need	abstract[63]	giv[63]	_	_
10-51	1153-1155	be	abstract[63]	giv[63]	_	_
10-52	1156-1165	inherited	abstract[63]	giv[63]	_	_
10-53	1166-1168	to	abstract[63]	giv[63]	_	_
10-54	1169-1173	pass	abstract[63]	giv[63]	_	_
10-55	1174-1177	the	abstract[63]|abstract[66]	giv[63]|new[66]	coref	11-20[72_66]
10-56	1178-1186	disorder	abstract[63]|abstract[66]	giv[63]|new[66]	_	_
10-57	1187-1188	.	_	_	_	_

#Text=A child of a parent with neurofibromatosis and an unaffected parent will have a 50 % chance of inheriting the disorder .
11-1	1189-1190	A	person[67]	new[67]	_	_
11-2	1191-1196	child	person[67]	new[67]	_	_
11-3	1197-1199	of	person[67]	new[67]	_	_
11-4	1200-1201	a	person[67]|person[68]	new[67]|new[68]	coref	11-9[70_68]
11-5	1202-1208	parent	person[67]|person[68]	new[67]|new[68]	_	_
11-6	1209-1213	with	person[67]|person[68]	new[67]|new[68]	_	_
11-7	1214-1231	neurofibromatosis	person[67]|person[68]|abstract	new[67]|new[68]|giv	coref	13-5[79_0]
11-8	1232-1235	and	person[67]|person[68]	new[67]|new[68]	_	_
11-9	1236-1238	an	person[67]|person[68]|person[70]	new[67]|new[68]|giv[70]	_	_
11-10	1239-1249	unaffected	person[67]|person[68]|person[70]	new[67]|new[68]|giv[70]	_	_
11-11	1250-1256	parent	person[67]|person[68]|person[70]	new[67]|new[68]|giv[70]	_	_
11-12	1257-1261	will	_	_	_	_
11-13	1262-1266	have	_	_	_	_
11-14	1267-1268	a	abstract[71]	new[71]	_	_
11-15	1269-1271	50	abstract[71]	new[71]	_	_
11-16	1272-1273	%	abstract[71]	new[71]	_	_
11-17	1274-1280	chance	abstract[71]	new[71]	_	_
11-18	1281-1283	of	abstract[71]	new[71]	_	_
11-19	1284-1294	inheriting	abstract[71]	new[71]	_	_
11-20	1295-1298	the	abstract[71]|abstract[72]	new[71]|giv[72]	_	_
11-21	1299-1307	disorder	abstract[71]|abstract[72]	new[71]|giv[72]	_	_
11-22	1308-1309	.	_	_	_	_

#Text=The gene responsible for NF-1 and possibly NF-2 is thought to function as a tumor suppressor gene .
12-1	1310-1313	The	abstract[73]	giv[73]	coref	12-14[77_73]
12-2	1314-1318	gene	abstract[73]	giv[73]	_	_
12-3	1319-1330	responsible	abstract[73]	giv[73]	_	_
12-4	1331-1334	for	abstract[73]	giv[73]	_	_
12-5	1335-1339	NF-1	abstract[73]|abstract	giv[73]|giv	_	_
12-6	1340-1343	and	abstract[73]	giv[73]	_	_
12-7	1344-1352	possibly	abstract[73]|abstract[75]	giv[73]|giv[75]	_	_
12-8	1353-1357	NF-2	abstract[73]|abstract[75]	giv[73]|giv[75]	_	_
12-9	1358-1360	is	_	_	_	_
12-10	1361-1368	thought	_	_	_	_
12-11	1369-1371	to	_	_	_	_
12-12	1372-1380	function	_	_	_	_
12-13	1381-1383	as	_	_	_	_
12-14	1384-1385	a	abstract[77]	giv[77]	_	_
12-15	1386-1391	tumor	person[76]|abstract[77]	new[76]|giv[77]	_	_
12-16	1392-1402	suppressor	person[76]|abstract[77]	new[76]|giv[77]	_	_
12-17	1403-1407	gene	abstract[77]	giv[77]	_	_
12-18	1408-1409	.	_	_	_	_

#Text=In most cases of neurofibromatosis 1 , patients can live normal and productive lives .
13-1	1410-1412	In	_	_	_	_
13-2	1413-1417	most	event[78]	new[78]	_	_
13-3	1418-1423	cases	event[78]	new[78]	_	_
13-4	1424-1426	of	event[78]	new[78]	_	_
13-5	1427-1444	neurofibromatosis	event[78]|abstract[79]	new[78]|giv[79]	coref	15-5[88_79]
13-6	1445-1446	1	event[78]|abstract[79]	new[78]|giv[79]	_	_
13-7	1447-1448	,	_	_	_	_
13-8	1449-1457	patients	person	new	coref	14-6
13-9	1458-1461	can	_	_	_	_
13-10	1462-1466	live	_	_	_	_
13-11	1467-1473	normal	abstract[81]	new[81]	_	_
13-12	1474-1477	and	abstract[81]	new[81]	_	_
13-13	1478-1488	productive	abstract[81]	new[81]	_	_
13-14	1489-1494	lives	abstract[81]	new[81]	_	_
13-15	1495-1496	.	_	_	_	_

#Text=In about 25-40 % of patients there is an associated learning disability with or without ADHD .
14-1	1497-1499	In	_	_	_	_
14-2	1500-1505	about	person[82]	new[82]	_	_
14-3	1506-1511	25-40	person[82]	new[82]	_	_
14-4	1512-1513	%	person[82]	new[82]	_	_
14-5	1514-1516	of	person[82]	new[82]	_	_
14-6	1517-1525	patients	person[82]|person	new[82]|giv	_	_
14-7	1526-1531	there	_	_	_	_
14-8	1532-1534	is	_	_	_	_
14-9	1535-1537	an	abstract[85]	new[85]	_	_
14-10	1538-1548	associated	abstract[85]	new[85]	_	_
14-11	1549-1557	learning	abstract|abstract[85]	new|new[85]	_	_
14-12	1558-1568	disability	abstract[85]	new[85]	_	_
14-13	1569-1573	with	abstract[85]	new[85]	_	_
14-14	1574-1576	or	abstract[85]	new[85]	_	_
14-15	1577-1584	without	abstract[85]	new[85]	_	_
14-16	1585-1589	ADHD	abstract[85]|abstract	new[85]|new	_	_
14-17	1590-1591	.	_	_	_	_

#Text=In some cases of neurofibromatosis 2 , the damage to nearby vital structures , such as the cranial nerves and the brainstem , can be life-threatening .
15-1	1592-1594	In	_	_	_	_
15-2	1595-1599	some	event[87]	new[87]	_	_
15-3	1600-1605	cases	event[87]	new[87]	_	_
15-4	1606-1608	of	event[87]	new[87]	_	_
15-5	1609-1626	neurofibromatosis	event[87]|abstract[88]	new[87]|giv[88]	coref	18-6[103_88]
15-6	1627-1628	2	event[87]|abstract[88]	new[87]|giv[88]	_	_
15-7	1629-1630	,	_	_	_	_
15-8	1631-1634	the	abstract[89]	new[89]	_	_
15-9	1635-1641	damage	abstract[89]	new[89]	_	_
15-10	1642-1644	to	abstract[89]	new[89]	_	_
15-11	1645-1651	nearby	abstract[89]|object[90]	new[89]|giv[90]	_	_
15-12	1652-1657	vital	abstract[89]|object[90]	new[89]|giv[90]	_	_
15-13	1658-1668	structures	abstract[89]|object[90]	new[89]|giv[90]	_	_
15-14	1669-1670	,	abstract[89]|object[90]	new[89]|giv[90]	_	_
15-15	1671-1675	such	abstract[89]|object[90]	new[89]|giv[90]	_	_
15-16	1676-1678	as	abstract[89]|object[90]	new[89]|giv[90]	_	_
15-17	1679-1682	the	abstract[89]|object[90]|abstract[91]|abstract[92]	new[89]|giv[90]|giv[91]|giv[92]	coref	15-17[92_91]
15-18	1683-1690	cranial	abstract[89]|object[90]|abstract[91]|abstract[92]	new[89]|giv[90]|giv[91]|giv[92]	_	_
15-19	1691-1697	nerves	abstract[89]|object[90]|abstract[91]|abstract[92]	new[89]|giv[90]|giv[91]|giv[92]	_	_
15-20	1698-1701	and	abstract[89]|object[90]|abstract[92]	new[89]|giv[90]|giv[92]	_	_
15-21	1702-1705	the	abstract[89]|object[90]|abstract[92]|object[93]	new[89]|giv[90]|giv[92]|new[93]	_	_
15-22	1706-1715	brainstem	abstract[89]|object[90]|abstract[92]|object[93]	new[89]|giv[90]|giv[92]|new[93]	_	_
15-23	1716-1717	,	_	_	_	_
15-24	1718-1721	can	_	_	_	_
15-25	1722-1724	be	_	_	_	_
15-26	1725-1741	life-threatening	_	_	_	_
15-27	1742-1743	.	_	_	_	_

#Text=When tumors are causing pain or disfiguration , surgery is thus far the only proven beneficial treatment option .
16-1	1744-1748	When	_	_	_	_
16-2	1749-1755	tumors	object|abstract[99]	giv|giv[99]	coref|coref	16-2[99_0]|18-20[107_0]
16-3	1756-1759	are	abstract[99]	giv[99]	_	_
16-4	1760-1767	causing	abstract[99]	giv[99]	_	_
16-5	1768-1772	pain	abstract|abstract[99]	new|giv[99]	_	_
16-6	1773-1775	or	abstract[99]	giv[99]	_	_
16-7	1776-1789	disfiguration	event|abstract[99]	new|giv[99]	_	_
16-8	1790-1791	,	abstract[99]	giv[99]	_	_
16-9	1792-1799	surgery	abstract|abstract[99]	new|giv[99]	_	_
16-10	1800-1802	is	abstract[99]	giv[99]	_	_
16-11	1803-1807	thus	abstract[99]	giv[99]	_	_
16-12	1808-1811	far	abstract[99]	giv[99]	_	_
16-13	1812-1815	the	abstract[99]	giv[99]	_	_
16-14	1816-1820	only	abstract[99]	giv[99]	_	_
16-15	1821-1827	proven	abstract[99]	giv[99]	_	_
16-16	1828-1838	beneficial	abstract[99]	giv[99]	_	_
16-17	1839-1848	treatment	event|abstract[99]	new|giv[99]	_	_
16-18	1849-1855	option	abstract[99]	giv[99]	_	_
16-19	1856-1857	.	_	_	_	_

#Text=Reggie Bibbs is a 43-year-old-man living in Houston , Texas .
17-1	1858-1864	Reggie	person[100]	giv[100]	coref	26-4[148_100]
17-2	1865-1870	Bibbs	person[100]	giv[100]	_	_
17-3	1871-1873	is	_	_	_	_
17-4	1874-1875	a	_	_	_	_
17-5	1876-1891	43-year-old-man	_	_	_	_
17-6	1892-1898	living	_	_	_	_
17-7	1899-1901	in	_	_	_	_
17-8	1902-1909	Houston	place[101]	new[101]	coref	26-16[152_101]
17-9	1910-1911	,	place[101]	new[101]	_	_
17-10	1912-1917	Texas	place[101]	new[101]	_	_
17-11	1918-1919	.	_	_	_	_

#Text=Mr Bibbs was born with a genetic disease called neurofibromatosis ( NF ) , which causes him to develop tumors on his body ( see infobox on the right ) .
18-1	1920-1922	Mr	person[102]	new[102]	ana	18-17[0_102]
18-2	1923-1928	Bibbs	person[102]	new[102]	_	_
18-3	1929-1932	was	_	_	_	_
18-4	1933-1937	born	_	_	_	_
18-5	1938-1942	with	_	_	_	_
18-6	1943-1944	a	abstract[103]	giv[103]	coref	18-10[0_103]
18-7	1945-1952	genetic	abstract[103]	giv[103]	_	_
18-8	1953-1960	disease	abstract[103]	giv[103]	_	_
18-9	1961-1967	called	abstract[103]	giv[103]	_	_
18-10	1968-1985	neurofibromatosis	abstract[103]|abstract	giv[103]|giv	coref	18-12
18-11	1986-1987	(	_	_	_	_
18-12	1988-1990	NF	abstract	giv	coref	19-1
18-13	1991-1992	)	_	_	_	_
18-14	1993-1994	,	_	_	_	_
18-15	1995-2000	which	_	_	_	_
18-16	2001-2007	causes	_	_	_	_
18-17	2008-2011	him	person	giv	ana	18-22
18-18	2012-2014	to	_	_	_	_
18-19	2015-2022	develop	_	_	_	_
18-20	2023-2029	tumors	object[107]	giv[107]	_	_
18-21	2030-2032	on	object[107]	giv[107]	_	_
18-22	2033-2036	his	object[107]|person|object[109]	giv[107]|giv|giv[109]	ana	19-13[0_109]
18-23	2037-2041	body	object[107]|object[109]	giv[107]|giv[109]	_	_
18-24	2042-2043	(	_	_	_	_
18-25	2044-2047	see	_	_	_	_
18-26	2048-2055	infobox	abstract[110]	giv[110]	_	_
18-27	2056-2058	on	abstract[110]	giv[110]	_	_
18-28	2059-2062	the	abstract[110]|abstract[111]	giv[110]|new[111]	_	_
18-29	2063-2068	right	abstract[110]|abstract[111]	giv[110]|new[111]	_	_
18-30	2069-2070	)	_	_	_	_
18-31	2071-2072	.	_	_	_	_

#Text=NF can be a subtle disease , but in Bibbs ' case it has left him with a disfigured face and deformed leg .
19-1	2073-2075	NF	abstract	giv	coref	19-4[113_0]
19-2	2076-2079	can	_	_	_	_
19-3	2080-2082	be	_	_	_	_
19-4	2083-2084	a	abstract[113]	giv[113]	coref	25-2[0_113]
19-5	2085-2091	subtle	abstract[113]	giv[113]	_	_
19-6	2092-2099	disease	abstract[113]	giv[113]	_	_
19-7	2100-2101	,	_	_	_	_
19-8	2102-2105	but	_	_	_	_
19-9	2106-2108	in	_	_	_	_
19-10	2109-2114	Bibbs	person[114]|abstract[115]	new[114]|new[115]	ana	19-16[0_114]
19-11	2115-2116	'	person[114]|abstract[115]	new[114]|new[115]	_	_
19-12	2117-2121	case	abstract[115]	new[115]	_	_
19-13	2122-2124	it	object	giv	_	_
19-14	2125-2128	has	_	_	_	_
19-15	2129-2133	left	_	_	_	_
19-16	2134-2137	him	person	giv	ana	20-2
19-17	2138-2142	with	_	_	_	_
19-18	2143-2144	a	object[118]	new[118]	_	_
19-19	2145-2155	disfigured	object[118]	new[118]	_	_
19-20	2156-2160	face	object[118]	new[118]	_	_
19-21	2161-2164	and	_	_	_	_
19-22	2165-2173	deformed	object[119]	new[119]	_	_
19-23	2174-2177	leg	object[119]	new[119]	_	_
19-24	2178-2179	.	_	_	_	_

#Text=But he is happy with the way he looks , and does n't want to change his appearance to please other people .
20-1	2180-2183	But	_	_	_	_
20-2	2184-2186	he	person	giv	ana	20-8
20-3	2187-2189	is	_	_	_	_
20-4	2190-2195	happy	_	_	_	_
20-5	2196-2200	with	_	_	_	_
20-6	2201-2204	the	abstract[121]	new[121]	_	_
20-7	2205-2208	way	abstract[121]	new[121]	_	_
20-8	2209-2211	he	abstract[121]|person	new[121]|giv	ana	20-17
20-9	2212-2217	looks	abstract[121]	new[121]	_	_
20-10	2218-2219	,	_	_	_	_
20-11	2220-2223	and	_	_	_	_
20-12	2224-2228	does	_	_	_	_
20-13	2229-2232	n't	_	_	_	_
20-14	2233-2237	want	_	_	_	_
20-15	2238-2240	to	_	_	_	_
20-16	2241-2247	change	_	_	_	_
20-17	2248-2251	his	person|abstract[124]	giv|new[124]	ana	21-1
20-18	2252-2262	appearance	abstract[124]	new[124]	_	_
20-19	2263-2265	to	_	_	_	_
20-20	2266-2272	please	_	_	_	_
20-21	2273-2278	other	person[125]	new[125]	ana	23-1[0_125]
20-22	2279-2285	people	person[125]	new[125]	_	_
20-23	2286-2287	.	_	_	_	_

#Text=He has launched a successful campaign entitled " Just Ask " , and that 's just what Wikinews did in a video-interview .
21-1	2288-2290	He	person	giv	_	_
21-2	2291-2294	has	_	_	_	_
21-3	2295-2303	launched	_	_	_	_
21-4	2304-2305	a	abstract[127]	new[127]	ana	21-14[0_127]
21-5	2306-2316	successful	abstract[127]	new[127]	_	_
21-6	2317-2325	campaign	abstract[127]	new[127]	_	_
21-7	2326-2334	entitled	abstract[127]	new[127]	_	_
21-8	2335-2336	"	abstract[127]	new[127]	_	_
21-9	2337-2341	Just	abstract[127]	new[127]	_	_
21-10	2342-2345	Ask	abstract[127]	new[127]	_	_
21-11	2346-2347	"	abstract[127]	new[127]	_	_
21-12	2348-2349	,	_	_	_	_
21-13	2350-2353	and	_	_	_	_
21-14	2354-2358	that	abstract	giv	_	_
21-15	2359-2361	's	_	_	_	_
21-16	2362-2366	just	_	_	_	_
21-17	2367-2371	what	_	_	_	_
21-18	2372-2380	Wikinews	organization	new	coref	22-6
21-19	2381-2384	did	_	_	_	_
21-20	2385-2387	in	_	_	_	_
21-21	2388-2389	a	abstract[130]	new[130]	_	_
21-22	2390-2405	video-interview	abstract[130]	new[130]	_	_
21-23	2406-2407	.	_	_	_	_

#Text=The interview was prepared by Wikinews reporter Michaël Laurent with the help of Bertalan Meskó ( who has a popular genetics and web 2.0 blog ) .
22-1	2408-2411	The	event[131]	new[131]	coref	24-1[144_131]
22-2	2412-2421	interview	event[131]	new[131]	_	_
22-3	2422-2425	was	_	_	_	_
22-4	2426-2434	prepared	_	_	_	_
22-5	2435-2437	by	_	_	_	_
22-6	2438-2446	Wikinews	organization|person[133]|abstract[134]	giv|new[133]|new[134]	_	_
22-7	2447-2455	reporter	person[133]|abstract[134]	new[133]|new[134]	_	_
22-8	2456-2463	Michaël	person[133]|abstract[134]	new[133]|new[134]	_	_
22-9	2464-2471	Laurent	person[133]|abstract[134]	new[133]|new[134]	_	_
22-10	2472-2476	with	_	_	_	_
22-11	2477-2480	the	abstract[135]	new[135]	_	_
22-12	2481-2485	help	abstract[135]	new[135]	_	_
22-13	2486-2488	of	abstract[135]	new[135]	_	_
22-14	2489-2497	Bertalan	abstract[135]|person[136]	new[135]|new[136]	_	_
22-15	2498-2503	Meskó	abstract[135]|person[136]	new[135]|new[136]	_	_
22-16	2504-2505	(	abstract[135]|person[136]	new[135]|new[136]	_	_
22-17	2506-2509	who	abstract[135]|person[136]	new[135]|new[136]	_	_
22-18	2510-2513	has	abstract[135]|person[136]	new[135]|new[136]	_	_
22-19	2514-2515	a	abstract[135]|person[136]|abstract[140]	new[135]|new[136]|new[140]	_	_
22-20	2516-2523	popular	abstract[135]|person[136]|abstract[140]	new[135]|new[136]|new[140]	_	_
22-21	2524-2532	genetics	abstract[135]|person[136]|abstract|abstract[140]	new[135]|new[136]|new|new[140]	_	_
22-22	2533-2536	and	abstract[135]|person[136]|abstract[140]	new[135]|new[136]|new[140]	_	_
22-23	2537-2540	web	abstract[135]|person[136]|abstract[138]|abstract[140]	new[135]|new[136]|new[138]|new[140]	_	_
22-24	2541-2544	2.0	abstract[135]|person[136]|abstract[138]|abstract|abstract[140]	new[135]|new[136]|new[138]|new|new[140]	_	_
22-25	2545-2549	blog	abstract[135]|person[136]|abstract[140]	new[135]|new[136]|new[140]	_	_
22-26	2550-2551	)	abstract[135]|person[136]	new[135]|new[136]	_	_
22-27	2552-2553	.	_	_	_	_

#Text=Their questions were sent to a close friend of Mr. Bibbs , Lou Congelio , who kindly conducted the interview .
23-1	2554-2559	Their	person|abstract[142]	giv|new[142]	_	_
23-2	2560-2569	questions	abstract[142]	new[142]	_	_
23-3	2570-2574	were	_	_	_	_
23-4	2575-2579	sent	_	_	_	_
23-5	2580-2582	to	_	_	_	_
23-6	2583-2584	a	person[143]	new[143]	_	_
23-7	2585-2590	close	person[143]	new[143]	_	_
23-8	2591-2597	friend	person[143]	new[143]	_	_
23-9	2598-2600	of	person[143]	new[143]	_	_
23-10	2601-2604	Mr.	person[143]	new[143]	_	_
23-11	2605-2610	Bibbs	person[143]	new[143]	_	_
23-12	2611-2612	,	person[143]	new[143]	_	_
23-13	2613-2616	Lou	person[143]	new[143]	_	_
23-14	2617-2625	Congelio	person[143]	new[143]	_	_
23-15	2626-2627	,	person[143]	new[143]	_	_
23-16	2628-2631	who	person[143]	new[143]	_	_
23-17	2632-2638	kindly	person[143]	new[143]	_	_
23-18	2639-2648	conducted	person[143]	new[143]	_	_
23-19	2649-2652	the	person[143]	new[143]	_	_
23-20	2653-2662	interview	person[143]	new[143]	_	_
23-21	2663-2664	.	_	_	_	_

#Text=The interview
24-1	2665-2668	The	event[144]	giv[144]	_	_
24-2	2669-2678	interview	event[144]	giv[144]	_	_

#Text=On neurofibromatosis
25-1	2679-2681	On	_	_	_	_
25-2	2682-2699	neurofibromatosis	abstract	giv	coref	27-13

#Text=My name is Reggie Bibbs , I am 43 years old and I live in Houston , Texas .
26-1	2700-2702	My	person|abstract[147]	acc|new[147]	ana	26-7
26-2	2703-2707	name	abstract[147]	new[147]	_	_
26-3	2708-2710	is	_	_	_	_
26-4	2711-2717	Reggie	person[148]	giv[148]	_	_
26-5	2718-2723	Bibbs	person[148]	giv[148]	_	_
26-6	2724-2725	,	_	_	_	_
26-7	2726-2727	I	person	giv	ana	26-13
26-8	2728-2730	am	_	_	_	_
26-9	2731-2733	43	time[150]	new[150]	_	_
26-10	2734-2739	years	time[150]	new[150]	_	_
26-11	2740-2743	old	_	_	_	_
26-12	2744-2747	and	_	_	_	_
26-13	2748-2749	I	person	giv	_	_
26-14	2750-2754	live	_	_	_	_
26-15	2755-2757	in	_	_	_	_
26-16	2758-2765	Houston	place[152]	giv[152]	_	_
26-17	2766-2767	,	place[152]	giv[152]	_	_
26-18	2768-2773	Texas	place[152]	giv[152]	_	_
26-19	2774-2775	.	_	_	_	_

#Text=Can you explain to our readers in simple terms what exactly is neurofibromatosis ?
27-1	2776-2779	Can	_	_	_	_
27-2	2780-2783	you	person	acc	_	_
27-3	2784-2791	explain	_	_	_	_
27-4	2792-2794	to	_	_	_	_
27-5	2795-2798	our	person|person[155]	acc|new[155]	_	_
27-6	2799-2806	readers	person[155]	new[155]	_	_
27-7	2807-2809	in	_	_	_	_
27-8	2810-2816	simple	abstract[156]	new[156]	_	_
27-9	2817-2822	terms	abstract[156]	new[156]	_	_
27-10	2823-2827	what	_	_	_	_
27-11	2828-2835	exactly	_	_	_	_
27-12	2836-2838	is	_	_	_	_
27-13	2839-2856	neurofibromatosis	abstract	giv	_	_
27-14	2857-2858	?	_	_	_	_
